Floatz logo

Gemtuzumab Ozogamicin

Adult Erythroleukemia (M6a)

National Cancer Institute (NCI)antibody_drug_conjugatePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Adult Erythroleukemia (M6a) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Northwestern University
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB
Idarubicine
Bruno C. Medeiros
Phase 3BBB

View all 50 →

Same molecule, other indications

Gemtuzumab Ozogamicin is also rated in:

leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →